Early asset assessment informing indication development

Goal

The client had an ongoing phase 2b read-out in a rare diseases dermatology indication for a biologic that will be launched in another immunology indication. In anticipation of the 52 weeks data read-out the client wanted to understand the unmet needs, prioritize the value drivers, assess the future competitors and derive the strategic implications for the future clinical development, by working closely with the global and US cross-functional teams.

Approach

Unmet needs

Map the current patient journey and prioritize the primary unmet needs

Value drivers

Prioritize value drivers based on impact for healthcare stakeholders

Future success

Assess future competitors and derive strategic implications

Early asset assessment informing indication development
Aligned the cross-functional global and US team on the unmet needs across all healthcare stakeholders
Prioritized the value drivers from a global perspective given currently available treatments
Assessed future competitors based on the still limited clinical evidence available in the public domain
Agreed on “market winning” & nice-to-have value drivers for further indication development

Contact our experts

Paul Gardiner

Director

Learn more about our focus topic

Early Asset Strategy

We use cookies to ensure we give you the best experience on our website. Detailed information on the use of cookies, and how you can disable them, is provided in our Privacy Policy. By using this site or clicking on "OK", you consent to the use of cookies.